Medical Products Group
5 of 35
Our Medical Products Group performed well in 2005, continuing to build a balanced array of innovation-driven, high-growth businesses in emerging areas of medical need.
Key accomplishments in 2005
- Delivered double-digit sales growth in the Medical Products Group.
- Achieved more than $1 billion in worldwide annual sales in Abbott Diabetes Care.
- Advanced development of our drug-eluting stent, ZoMaxx, by completing enrollment in ZOMAXX I, our European trial, and continuing enrollment in ZOMAXX II, our primarily North American trial.
- Received U.S. FDA approval for, and launched, the Xact and Emboshield carotid stent system and the StarClose vessel closure device.
- Launched Abbott Prism, installing the world’s first fully automated blood screening instrument in regional blood centers across the United States.
